|
Notable growth in 2013
2014.03.11
|
|---|
|
Remarkable Growth in 2013
- Sales up 18.1% and operating profit up 72.6% year-on-year - Record-breaking quarterly results since 2012 - Differentiated obesity solutions, strengthened distribution network and customer loyalty, and talent-driven management as key growth drivers
Daehan New Pharm achieved notable results in 2013.
Despite a rapidly changing pharmaceutical environment, including continuous drug price cuts and tighter distribution regulations, the company recorded total sales of 56.7 billion KRW, up 18.1% from the previous year, and operating profit of 5.96 billion KRW, a 72.6% increase.
This achievement reflects Daehan New Pharm’s consistent record-setting growth each quarter since 2012.
The main growth engines were strategic innovation initiatives that reinforced leadership in the wellness and beauty solutions sector, particularly through differentiated obesity management solutions. The company also strengthened its distribution network by directly managing hospitals and clinics, securing valuable customer assets, and enhancing brand loyalty.
Key drivers of competitiveness included the successful market response to newly launched, pioneering products and the focused development of strategic items. Furthermore, the company embedded talent-centered management as part of its corporate DNA, fostering and developing core personnel to strengthen creative sales capabilities. The sharp rise in operating profit resulted from both top-line growth and cost optimization through a well-structured product portfolio, in addition to improved per-capita productivity.
Moving forward, Daehan New Pharm will continue pursuing strategic innovation that creates new value and differentiation, accelerate creative sales activities that enhance customer loyalty, and expand talent-focused management to drive sustainable growth. |


Home